| Page 9 | Kisaco Research
 

Yann Dietrichh

Group Head of IP
Atos

Yann Dietrichh

Group Head of IP
Atos

Yann Dietrichh

Group Head of IP
Atos
Innovation Showcase Info Pack

Supplementary Protection Certificates remain a critical and complex aspect of pharmaceutical patent strategy. This session offers a comprehensive review of recent landmark rulings and evolving practices across Europe, providing life sciences patent holders with key insights to refine their SPC approaches in 2025.


• Explore pivotal cases such as Teva/MSD and Halozyme, and their impact on Articles 3(a), 3(c), and 1(b) concerning combination products and active ingredient interpretation.
• Understand how recent UK decisions, including Merck v Comptroller (2025), reflect divergence from broader European SPC practice, and examine emerging trends in antibody SPCs and unitary SPC legal status.
• Examine the expanded SPC Manufacturing Waiver regime since 2022, including conflicting rulings from Belgium, Germany, and the Netherlands on storage, export, and notification requirements.
• Gain practical guidance on managing waiver-related risks, protecting exclusivity, and navigating cross-jurisdictional challenges in SPC enforcement and litigation.

Author:

Karin Pramberger

Head of IP
Polpharma Group

Karin has been Intellectual Property Director at the Polpharma Group since April 2018. She is responsible for all patent and trade mark related activities. Prior to joining the Polpharma Group, Karin was Head of IP of Medichem, Spain, and worked in various positions within the patent department of Teva, Barr and Pliva.  She spent 7 years in a law firm in Vienna, Austria, where she became European and Austrian patent and trade mark attorney. She studied Biotechnology in Vienna, Austria, and at the Ecole Nationale Supérieure de Chemie de Paris, France. In 2017 she graduated with an LLB from the University of London. Since 2005 she has been a tutor at CEIPI, University of Strasbourg, for the pre-exam and the C-part of the European Qualifying Exam. 

Karin Pramberger

Head of IP
Polpharma Group

Karin has been Intellectual Property Director at the Polpharma Group since April 2018. She is responsible for all patent and trade mark related activities. Prior to joining the Polpharma Group, Karin was Head of IP of Medichem, Spain, and worked in various positions within the patent department of Teva, Barr and Pliva.  She spent 7 years in a law firm in Vienna, Austria, where she became European and Austrian patent and trade mark attorney. She studied Biotechnology in Vienna, Austria, and at the Ecole Nationale Supérieure de Chemie de Paris, France. In 2017 she graduated with an LLB from the University of London. Since 2005 she has been a tutor at CEIPI, University of Strasbourg, for the pre-exam and the C-part of the European Qualifying Exam. 

Author:

Sebastian Moore

Partner
HSF Kramer

Sebastian Moore

Partner
HSF Kramer
 

James Holtom

Partner
McCarthy Tetrault

James Holtom

Partner
McCarthy Tetrault

James Holtom

Partner
McCarthy Tetrault
 

Ken Aduddell

Senior Director
actnano

Ken Aduddell is a thought leader in data infrastructure with over 20 years of experience in the electronics industry. A trusted partner to executives at hyperscalers, his work has focused on the core challenges of data center resilience, including power and coolant systems. An established contributor to the Open Compute Project on the data center resilience chain, Ken offers deep insight into de-risking the inevitable transition to direct liquid cooling and protecting the mission-critical assets that power the AI era.

Ken Aduddell

Senior Director
actnano

Ken Aduddell

Senior Director
actnano

Ken Aduddell is a thought leader in data infrastructure with over 20 years of experience in the electronics industry. A trusted partner to executives at hyperscalers, his work has focused on the core challenges of data center resilience, including power and coolant systems. An established contributor to the Open Compute Project on the data center resilience chain, Ken offers deep insight into de-risking the inevitable transition to direct liquid cooling and protecting the mission-critical assets that power the AI era. Previously at Rockwell Automation, Ken now leads actnano's initiative to protect critical hardware with this breakthrough coating technology.

 

Sebastian Moore

Partner
HSF Kramer

Sebastian Moore

Partner
HSF Kramer

Sebastian Moore

Partner
HSF Kramer
 

Richard Roberts

Partner
Potter Clarkson

Richard Roberts

Partner
Potter Clarkson

Richard Roberts

Partner
Potter Clarkson
 

Jin Ooi

Partner
Kirkland & Ellis

Jin Ooi

Partner
Kirkland & Ellis

Jin Ooi

Partner
Kirkland & Ellis
 

Markus Gruber

Head IP Solid Tumours & Radioligland Therapies
Novartis

Markus Gruber

Head IP Solid Tumours & Radioligland Therapies
Novartis

Markus Gruber

Head IP Solid Tumours & Radioligland Therapies
Novartis